|Keywords:||Atopic Dermatitis, Eczema|
|Type:||Drug Study, Phase 3|
Applicable patients should be diagnosed with moderate to severe atopic dermatitis according to the guidelines set by the American Academy of Dermatology. Study products will be taken orally in tablet-form daily. A more in-depth explanation of the study protocol and treatment overview will take place during initial screening.
Inclusion Criteria: Diagnosis of atopic dermatitis > 12 months; Moderate to severe atopic dermatitis with BSA >10%: Uncontrolled with topical corticosteriods OR failed systemic therapies (i.e., cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil) within 6 months of screening
Exclusion Criteria: Patients who have documented: Other active concomitant skin conditions (ex: lupus, psoriasis); Current or recent serious medical condition or infection; Immunodeficiency; Concomitant illnesses requiring systemic corticosteriods; At risk for or history of blood clots in legs or lungs; Received a live vaccine within 12 weeks of Visit 2 or need to receive one during the study duration; Alcohol or drug abuse within the last 2 years of Visit 1; Pregnant or breast feeding